Remepy Pre-Seed

Remepy pioneers Hybrid Drugs, a new class of medicine integrating pharmaceutical molecules with AI-driven digital protocols delivered via app. These Hybrid Drugs measurably improve motor, cognitive, and mental function, with their first product, Hybridopa, targeting Parkinson's Disease. Remepy's approach is regulated like medicine, adaptive like software, and reimbursed like pharma, aiming to deliver superior outcomes.